Navigation Links
Dendreon Reports First Quarter 2011 Financial Results
Date:5/2/2011

target cancer and transform lives through the discovery, development, commercialization and manufacturing of novel therapeutics. The Company applies its expertise in antigen identification, engineering and cell processing to produce active cellular immunotherapy (ACI) product candidates designed to stimulate an immune response in a variety of tumor types. Dendreon's first product, PROVENGE® (sipuleucel-T), was approved by the U.S. Food and Drug Administration (FDA) in April 2010. Dendreon is exploring the application of additional ACI product candidates and small molecules for the potential treatment of a variety of cancers. The Company is headquartered in Seattle, Washington and is traded on the NASDAQ Global Market under the symbol DNDN. For more information about the Company and its programs, visit http://www.dendreon.com/.

This news release contains forward-looking statements that are subject to risks and uncertainties. Factors that could affect these forward-looking statements include, but are not limited to, developments affecting Dendreon's business and prospects, including progress on the commercialization efforts for PROVENGE.  Information on the factors and risks that could affect Dendreon's business, financial condition and results of operations are contained in Dendreon's public disclosure filings with the U.S. Securities and Exchange Commission, which are available at www.sec.gov. Dendreon cautions investors not to place undue reliance on the forward-looking statements contained in this press release. All forward-looking statements are based on information currently available to Dendreon on the date hereof, and Dendreon undertakes no obligation to revise or update these forward-looking statements to reflect events or circumstances after the date of this press release, except as required by law. DENDREON CORPORATIONCONSOLI
'/>"/>

SOURCE Dendreon Corporation
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Dendreon to Host Conference Call on May 2, 2011 to Announce First Quarter 2011 Financial Results
2. Dendreon Reports Fourth Quarter and 2010 Year End Financial Results
3. Dendreon Announces Webcast Presentations at Four Upcoming Conferences
4. Dendreon Announces Presentation of PROVENGE Data at the 2011 Genitourinary Cancers Symposium Annual Meeting
5. Dendreon to Host Conference Call on March 1st to Announce Fourth Quarter and Year-End Financial Results
6. Dendreon Announces Pricing of $540 Million Convertible Senior Notes Due 2016
7. Dendreon Announces Plans to Seek Marketing Authorization for PROVENGE in Europe
8. Dendreon to Host Conference Call to Provide Updates on U.S. Commercialization Progress, European Strategy for PROVENGE, and Pipeline Progress
9. Dendreon Announces MEDCAC Panel Reviewed PROVENGE Evidence
10. Dendreon Submits Post-Approval Supplement to the PROVENGE Biologics License Application for New Jersey Manufacturing Facility
11. Dendreon to Host Conference Call on November 3rd to Announce Third Quarter Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/25/2014)... and NEW YORK , ... (OTCQB: ACCPD), formerly Access Pharmaceuticals, Inc. (ACCP), a ... announced it has implemented a 1-for-50 reverse split ... of trading on Friday, October 24, 2014. PlasmaTech,s ... under new CUSIP number 72754H109 and temporary ticker ...
(Date:10/25/2014)... , October 24, 2014 ... http://www.researchandmarkets.com/research/t5t5pd/the_global_market ) has announced the addition of ... Graphene And Other 2-D Nanomaterials "  report ... http://photos.prnewswire.com/prnh/20130307/600769) , ,CNTs and graphene are the ... to man, with a performance-per-weight greater than ...
(Date:10/22/2014)... 21, 2014 The Americas Inorganic ... refrigerants market in Americas with analysis and forecast ... the Americas Inorganic Refrigerants Market report, to get ... also provides a glimpse of the segmentation in ... by various tables and figures. , ...
(Date:10/22/2014)... WriteResult, LLC – a premier ... working with a team of researchers from Yale University’s ... Farming Collaborative to provide electronic questionnaire data collection through ... which started in May, aims to evaluate the impact ... exposure to and participation in urban agriculture to impact ...
Breaking Biology Technology:PlasmaTech Biopharmaceuticals, Inc. Announces Reverse Stock Split, Ticker Change and Launches New Corporate Website 2The Global Market for Carbon Nanotubes, Graphene and Other 2-D Nanomaterials 2The Global Market for Carbon Nanotubes, Graphene and Other 2-D Nanomaterials 3The Global Market for Carbon Nanotubes, Graphene and Other 2-D Nanomaterials 4The Americas Inorganic Refrigerants Market is estimated to grow to $71.6 million by 2018 - New Report by MicroMarket Monitor 2The Americas Inorganic Refrigerants Market is estimated to grow to $71.6 million by 2018 - New Report by MicroMarket Monitor 3myPROpad™ Topic of Panel Discussion at the Yale Food Systems Symposium 2myPROpad™ Topic of Panel Discussion at the Yale Food Systems Symposium 3
... international scientific ... ... of antibody fragment therapeutics, today announced that it has,achieved high concentrations ... delivery via eye drops. These data were confirmed in,several independent preclinical ...
... from sunlight falling on only 9 percent of ... United States electricity needs if the energy could ... current-generation solar cell technologies are too expensive and ... of Northwestern University researchers has developed a new ...
... Monday, February 25, 2008 at ... ... Biopharmaceuticals,Inc. (Nasdaq: KERX ), a biopharmaceutical company focused on the,acquisition, ... of life-threatening,diseases, including diabetes and cancer (the "Company"), today announced,its results ...
Cached Biology Technology:ESBATech's Antibody Fragments Demonstrate Penetration into the Eye with Topical Delivery via Eye Drops 2ESBATech's Antibody Fragments Demonstrate Penetration into the Eye with Topical Delivery via Eye Drops 3Special coating greatly improves solar cell performance 2Keryx Biopharmaceuticals, Inc. Announces Fourth Quarter and Year-End 2007 Financial Results 2Keryx Biopharmaceuticals, Inc. Announces Fourth Quarter and Year-End 2007 Financial Results 3Keryx Biopharmaceuticals, Inc. Announces Fourth Quarter and Year-End 2007 Financial Results 4Keryx Biopharmaceuticals, Inc. Announces Fourth Quarter and Year-End 2007 Financial Results 5Keryx Biopharmaceuticals, Inc. Announces Fourth Quarter and Year-End 2007 Financial Results 6
(Date:10/22/2014)... Northwestern Medicine® scientists helps explain how bipolar disorder affects ... drug therapies to treat the mental illness. , ... same method recognized with the 2014 Nobel Prize ... tissue from mice with bipolar-like behaviors. In the synapses ... "nanodomain" structures with concentrated levels of ANK3 -- the ...
(Date:10/18/2014)... 2014 Psychological stress and stress-related psychiatric disorders are ... but the molecular mechanisms underlying this relation ... to the development of targeted preventive strategies ... devastating diseases. This work is presented at ... Berlin., Now an international group of researchers ...
(Date:10/17/2014)... University of Copenhagen have shown for the first time ... Cystic fibrosis patients, giving them the opportunity to get ... infections. , The study also discovered the bacterial growth ... was halted or slowed down by the immune cells. ... oxygen and helped "suffocate" the bacteria, forcing the bacteria ...
Breaking Biology News(10 mins):Bipolar disorder discovery at the nano level 2Researchers find why depression and aging linked to increased disease risk 2Scientists opens black box on bacterial growth in cystic fibrosis lung infection 2
... a corporation has a public relations crisis, the news media ... to new research in the Journal of Consumer Research the ... and the situation. "A company can control what face ... the face shape of this person is not a trivial ...
... better at making product choices, according to a new ... who understand their emotional ability can make higher quality ... explain the authors, Blair Kidwell, David M. Hardesty, and ... know a lot about nutrition and know what foods ...
... PROVIDENCE, R.I. [Brown University] Imagine being paralyzed, unable to ... to five million Americans suffer from this debilitating situation. Or ... millions of Americans are affected by these infirmities. Now ... your hands or arms enough to tap out an e-mail ...
Cached Biology News:Brown to host conference on advances in neurotechnology 2Brown to host conference on advances in neurotechnology 3
... The T2-04 is an ultra-compact pump available ... (T2-04 TH) and ideal for use in portable ... 7 slpm, this pump works well in environments ... weight, and compact size are critical., Offers ...
XA7 B6...
Curcumin is an extract of turmeric root with antioxidant, anti-tumor promoter, and anti-inflammatory properties. Curcumin inhibits the induction of NOS in macrophages....
... The MEGAscript RNAi Kit ... of large mass amounts of ... in non-mammalian systems. The MEGAscript ... Ambions patented high-yield transcription technol-ogy ...
Biology Products: